Table 3

Study 203

 Mean (X) and Mean Change (∆) from Baseline in 17-item HAMD

LAST OBSERVATION CARRIED FORWARD ANALYSIS

Treatment

Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

120

23.1

113

-2.9

120

-5.6

120

-7.9

120

-8.9

120

-9.0

120

-9.4

120

-10.0

120

-10.2

BUP SR 300 (II)

113

23.4

113

-2.7

113

-4.8

113

-7.0

113

-8.0

113

-8.6

113

-8.9

113

-9.6

113

-10.2

Placebo (P)

117

23.2

116

-3.2

117

-5.2

117

-6.2

117

-7.0

117

-7.5

117

-7.6

117

-7.8

117

-8.1

2-sided p-values for pairwise comparisons

I. vs. P

>0.5

0.58

0.48

0.036

0.025

0.081

0.056

0.027

0.033

II vs. P

>0.5

.042

0.58

0.36

0.22

0.23

0.18

0.072

0.040

OBSERVED CASES ANALYSIS

Treatment

Groups

Treatment Week

Baseline

Wk 1

Wk 2

Wk 3

Wk 4

Wk 5

Wk 6

Wk 7

Wk 8

N

X

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

N

∆

BUP SR 150 (L)

120

23.1

113

-2.9

109

-5.9

98

-8.5

89

-10.3

83

-10.9

70

-12.4

67

-13.5

64

-14.1

BUP SR 300 (II)

113

23.4

113

-2.7

100

-4.9

98

-7.7

87

-9.3

77

-10.4

74

-11.8

69

-13.1

62

-14.8

Placebo (P)

117

23.2

116

-3.2

112

-5.2

102

-7.0

91

-8.2

75

-9.5

69

-11.5

64

-12.3

56

-12.8

2-sided p-values for pairwise comparisons

I. vs. P

>0.5

0.58

.30

0.074

0.029

0.167

0.304

0.184

0.149

II vs. P

>0.5

.042

0.70

0.41

0.24

0.47

0.80

0.46

0.10